EXHIBIT 12.1
Ratio of Earnings to Fixed Charges | ||||||||||||||||||||||||
(dollars in thousands, except ratio data) | ||||||||||||||||||||||||
March 31, | December 31, | December 31, | December 31, | December 31, | December 31, | |||||||||||||||||||
2005 | 2004 | 2003 | 2002 | 2001 | 2000 | |||||||||||||||||||
Fixed Charges: | ||||||||||||||||||||||||
Interest expense on indebtedness (including amortization of debt expense and discount) | $ | 4,707 | $ | 22,868 | $ | 23,723 | $ | 23,746 | $ | 24,638 | $ | 22,088 | ||||||||||||
Interest expense on portion of rent expense representative of interest | 3,265 | 9,089 | 7,604 | 7,206 | 6,159 | 3,251 | ||||||||||||||||||
Total Fixed Charges | $ | 7,972 | $ | 31,957 | $ | 31,327 | $ | 30,952 | $ | 30,797 | $ | 25,339 | ||||||||||||
Earnings (Loss): | ||||||||||||||||||||||||
Net loss before provision for income taxes and cumulative effect of change in accounting principle | $ | (59,582 | ) | $ | (242,898 | ) | $ | (185,324 | ) | $ | (219,716 | ) | $ | (117,152 | ) | $ | (235,331 | ) | ||||||
Fixed Charges per above | 7,972 | 31,957 | 31,327 | 30,952 | 30,797 | 25,339 | ||||||||||||||||||
Total Earnings (Loss) | $ | (51,610 | ) | $ | (210,941 | ) | $ | (153,997 | ) | $ | (188,764 | ) | $ | (86,355 | ) | $ | (209,992 | ) | ||||||
Ratio of Earnings to Fixed Charges | — | — | — | — | — | — | ||||||||||||||||||
Coverage deficiency(1)(2)(3)(4) | $ | (59,582 | ) | $ | (242,898 | ) | $ | (185,324 | ) | $ | (219,716 | ) | $ | (117,152 | ) | $ | (235,331 | ) | ||||||
(1) | The Company’s Coverage deficiency for 2004 includes net charges of $12,975, relating to a $15,408 charge for restructuring partially offset by a gain recognized on the extinguishment of debt of $2,433. | |
(2) | The Company’s Coverage deficiency for 2002 includes charges aggregating $46,396 arising from the Company’s impairment charge relating to its investment in CAT and a charge for construction design changes of $32,158 and $14,238, respectively. | |
(3) | The Company’s Coverage deficiency for 2001 includes charges aggregating $26,208 arising from the Company’s impairment charge relating to its investment in Transgene and debt conversion expenses of $22,314 and $3,894, respectively. | |
(4) | The Company’s Coverage deficiency for 2000 includes charges aggregating $184,868 arising from purchased in-process research and development and debt conversion expenses of $134,050 and $50,818, respectively. |